Protiveriss mission is to commercialize microcantilever technology to aid in the launch of new pharmaceuticals by accelerating the drug discovery and development process.

While there have been numerous advances in genomic research tools, limited progress has been made in the development of effective tools for proteomic research. Thousands of "druggable" protein targets - the primary site of drug action Т– have yet to be researched. As a result, there is a tremendous unmet need in both the drug discovery and diagnostic industries for tools that enable increased understanding of proteins and their functions and interactions.
Protiveris intends to fulfill the promise of proteomics by developing technology and instrumentation that will establish a standard of performance and revolutionize drug discovery research.

Microcantilevers offer a highly flexible, label-free sensor platform for detecting small molecules and proteins in either liquid or gas environments.

Microcantilevers's sensitivity allows for use of nanoliters of sample volumes, thereby preserving precious reagents such as chemical libraries. Furthermore, samples to be analyzed do not require exhaustive manipulation or labeling - no dyes, fluorescents, stains, or tracers. Label-free detection not only reduces costs and experiment time, but more specifically, eliminates the conformational changes that can alter binding properties and functionality. The sensitivity of Protiveris's specially designed microcantilevers for ultra-low force detection, combined with the flexibility of Protiveris's arrays, make this technology superior to existing biosensor technologies.